Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jul;60(1):101-102.
doi: 10.1111/apt.18049. Epub 2024 May 23.

Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease

Maryam Alahmad  1 , Mohammed Nabil Quraishi  1 , Shaima Wasim Khan  1 , Nadeen Mamon Omar  1 , Talha A Malik  1   2
Affiliations
Comment

Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease

Maryam Alahmad et al. Aliment Pharmacol Ther. 2024 Jul.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59:1312–1334.
    1. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet Lond Engl. 2022;399(10340):2015–2030.
    1. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double‐blind, placebo‐controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet Lond Engl. 2022;399(10340):2031–2046.
    1. Ferrante M, Panaccione R, Colombel JF, Dubinsky M, Hisamatsu T, Lindsay JO, et al. DOP53 long‐term efficacy and safety of Risankizumab in patients with moderate to severe Crohn's disease up to 3 years of treatment: results from the FORTIFY open‐label long‐term extension. J Crohns Colitis. 2024;18(Suppl._1):i168–i170.
    1. Peyrin‐Biroulet L, Bossuyt P, Regueiro M, Schreiber S, Gecse K, Irving P, et al. DOP10 Risankizumab versus Ustekinumab for the achievement of endoscopic outcomes in patients with moderate‐to‐severe Crohn's disease: results from the phase 3b SEQUENCE trial. J Crohns Colitis. 2024;18(Suppl._1):i90–i91.

LinkOut - more resources